B

BiohacksAI

Evidence-Based Biohacking

Patent Pending

KCNJ1

MOLECULAR TARGET

potassium inwardly rectifying channel subfamily J member 1

UniProt: P48048NCBI Gene: 37583 compounds

KCNJ1 (potassium inwardly rectifying channel subfamily J member 1) is targeted by 3 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).

Compounds Targeting KCNJ1

Ranked by bioassay confidence score (PubChem active assay count × evidence quality).

#CompoundConfidenceActive Assays
1Progesterone0.691
2dihydrorotenone0.691
3streptonigrin0.691

About KCNJ1 as a Drug Target

KCNJ1 (potassium inwardly rectifying channel subfamily J member 1) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 3 compounds with documented KCNJ1 interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.

KCNJ1 inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.